Recep Civan YÜKSEL, Muhammet GÜVEN, Arzu TOPELİ, Ebru ORTAÇ ERSOY, Murat SUNGUR, Melda TÜRKOĞLU, Uğur ÖZDEMİR, Gülbin AYGENCEL, Erhan KAYA, Neriman Defne ALTINTAŞ

Value of prognostic scores in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis patients in intensive care unit: a multicenter retrospective cohort study from Turkey

Background/aim: There is a need for a scoring system for predicting ICU prognosis of patients with ANCA-associated vasculitis (AAV), but there are limited data on it in the literature. Therefore, we aimed to determine the scores that can estimate the prognosis of patients with AAV during intensive care follow up. Materials and methods: All adult patients admitted to the medical ICUs of 4 reference university hospitals in Turkey due to AAV activation and/or disease/treatment complications in the last 10 years were included in this study. Demographic data, treatments before ICU, the Birmingham Vasculitis Activity Score (BVAS) score at the time of vasculitis diagnosis, and BVAS, APACHE II, SOFA, and SAPS II scores at the ICU admission, treatments, procedures, and complications during ICU stay were recorded for all AAV patients. Results: Thirty-four patients were included in the study. The median age of the patients was 60 (42–70) years, and 64.7% were male. Twenty-five patients were diagnosed with Granulomatosis with polyangiitis, and 9 were diagnosed with Microscopic polyangiitis. The most common ICU admission causes were hemorrhage (85.3%) and sepsis/septic shock (67.6%). Twenty patients (58.8%) died in the ICU follow up. There were significant differences in APACHE II (P = 0.004) and SAPS II (P = 0.044) scores between survivors and nonsurvivors, while there were no significant differences in BVAS (during diagnosis P = 0.089 and ICU admission P = 0.539) and SOFA (P = 0.097) scores. APACHE II score was found to be an independent risk factor for ICU mortality (OR = 1.231, CI 95% = 1.011–1.498, P = 0.038) according to logistic regression analysis. An APACHE II score of greater than 20.5 predicted ICU mortality with 80% sensitivity and 70% specificity (AUC = 0.8, P = 0.004, Likelihood ratio = 2.6) according to the ROC curve analysis. Conclusion: APACHE II score can be used for the prediction of ICU mortality in AAV patients.

PDF

___

1. Nakazawa D, Masuda S, Tomaru U, Ishizu A. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nature Reviews Rheumatology 2019; 15(2): 123. doi: 10.1038/ s41584-019-0168-z
2. Holguin F, Ramadan B, Gal AA, Roman J. Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. American Journal of the Medical Sciences 2008; 336(4): 321-326. doi: 10.1097/ MAJ.0b013e31816805fa
3. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism 2013; 65(1): 1-11. doi: 10.1002/art.37715
4. Frausova D, Brejnikova M, Hruskova Z, Rihova Z, Tesar V. Outcome of thirty patients with ANCA-associated renal vasculitis admitted to the intensive care unit. Renal Failure 2008; 30(9): 890-895. doi: 10.1080/08860220802353892
5. Janssen NM, Karnad DR, Guntupalli KK. Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome. Critical Care Clinics 2002; 18(4): 729-748. Review doi: 10.1016/s0749-0704(02)00025-8
6. Vincent JL, Moreno R. Clinical review: scoring systems in the critically ill. Critical Care (London, England) 2010; 14(2): 207. doi: 10.1186/cc8204
7. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM: Monthly Journal of the Association of Physicians 1994; 87(11): 671-678.
8. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Annals of the Rheumatic Diseases 2009; 68(12): 1827-1832. doi: 10.1136/ard.2008.101279
9. Suppiah R, Mukhtyar C, Flossmann O, Alberici F, Baslund B et al. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology (Oxford, England) 2011; 50(5): 899-905. doi: 10.1093/ rheumatology/keq400
10. Demiselle J, Auchabie J, Beloncle F, Gatault P, Grangé S et al. Patients with ANCA-associated vasculitis admitted to the intensive care unit with acute vasculitis manifestations: a retrospective and comparative multicentric study. Annals of Intensive Care 2017; 7(1): 39. doi: 10.1186/s13613-017-0262-9
11. Khan SA, Subla MR, Behl D, Specks U, Afessa B. Outcome of patients with small-vessel vasculitis admitted to a medical ICU. Chest 2007; 131(4): 972-976.
12. Cruz BA, Ramanoelina J, Mahr A, Cohen P, Mouthon L et al. Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. Rheumatology (Oxford, England) 2003; 42(10): 1183-1188. doi: 10.1093/ rheumatology/keg322
13. Kimmoun A, Baux E, Das V, Terzi N, Talec P et al. Outcomes of patients admitted to intensive care units for acute manifestation of small-vessel vasculitis: a multicenter, retrospective study. Critical Care (London, England) 2016; 26; 20:27. doi: 10.1186/ s13054-016-1189-5
14. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B et al. Development and validation of aconsensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Annals of the Rheumatic Diseases 2007; 66(2): 222-227. doi: 10.1136/ ard.2006.054593
15. Mun CH, Yoo J, Jung SM, Song JJ, Park YB et al. The initial predictors of death in 153 patients with ANCA-associated vasculitis in a single Korean centre. Clinical and Experimental Rheumatology 2018; 111(2): 65-72.
16. Pu L, Li GS, Zou YR, Zhang P, Wang L. Clinical Predictors of Outcome in Patients with Antineutrophil Cytoplasmic Autoantibody-related Renal vasculitis: Experiences from a Single-center. Chinese Medical Journal 2017; 130(8): 899-905. doi: 10.4103/0366-6999.204099
17. Ozbalkan Z, Topeli A, Kiraz S, Ozturk MA, Ertenli I et al. The contribution of underlying systemic rheumatic diseases to the mortality in patients admitted for intensive care: a matched cohort study. Clinical and Experimental Rheumatology 2004; 22(2): 223-226.
18. Włudarczyk A, Polok K, Górka J, Hałek A, Biedroń G et al. Patients with small-vessel vasculitides have the highest mortality among systemic autoimmune diseases patients treated in intensive care unit: A retrospective study with 5– year follow up. Journal of Critical Care 2018; 48: 166-171. doi: 10.1016/j.jcrc.2018.08.037
19. Burkhardt O, Köhnlein T, Wrenger E, Lux A, Neumann KH et al. Predicting outcome and survival in patients with Wegener’s granulomatosis treated on the intensive care unit. Scandinavian Journal of Rheumatology 2007; 36(2): 119-24. doi: 10.1080/03009740600958611
20. Biscetti F, Carbonella A, Parisi F, Bosello SL, Schiavon F et al. The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). Medicine (Baltimore) 2016; 95(48): e5506. doi: 10.1097/MD.0000000000005506
21. Solans-Laqué R, Rodriguez-Carballeira M, Rios-Blanco JJ, Fraile G, Sáez-Comet L et al. Spanish Registry of systemic vasculitis (REVAS); Autoimmune Systemic Diseases Study Group (GEAS); Spanish Society of Internal Medicine (SEMI). Comparison of the Birmingham vasculitis activity score and the five factors score to assess survival in ANCA-associated vasculitis. Arthritis Care & Research (Hoboken) 2019. doi: 10.1002/acr.23912